Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480-Reference-Cited by-同舟云学术

Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480

Published:2011-03 Issue:3 Volume:55 Page:1287-1289
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Alffenaar J. W. C.¹,van der Laan T.²,Simons S.³,van der Werf T. S.⁴,van de Kasteele P. J.⁵,de Neeling H.²,van Soolingen D.²³

Affiliation:

1. Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

2. National Mycobacteria Reference Laboratory, National Institute for Public Health and the Environment, Bilthoven, Netherlands

3. Radboud University Nijmegen Medical Centre, Dekkerswald, and Medical Microbiology, Nijmegen, Netherlands

4. Departments of Internal Medicine and of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

5. Expertise Centre for Methodology and Information Services, National Institute for Public Health and the Environment, Bilthoven, Netherlands

Abstract

ABSTRACT Susceptibility of clinical Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system. The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin. The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid. Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01297-10

Reference27 articles.

1. In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis That Are Susceptible or Resistant to First-Line Antituberculous Drugs

2. Alffenaar J. W. C. et al. 2010. Comparison of pharmacokinetics of two dosage regime of linezolid in MDR/XDR-TB patients. Clin. Pharmacokinet. 49 : 559-565.

3. Borrell, S., and S. Gagneux. 2009. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13:1456-1466.

4. Bressler, A. M., S. M. Zimmer, J. L. Gilmore, and J. Somani. 2004. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect. Dis. 4:528-531.

5. Brickner, S. J., et al. 1996. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J. Med. Chem. 39:673-679.

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?;Pharmaceutics;2024-06-17

2. Recent advances in the exploration of oxazolidinone scaffolds from compound development to antibacterial agents and other bioactivities;European Journal of Medicinal Chemistry;2024-04

3. Antibiotics in the clinical pipeline as of December 2022;The Journal of Antibiotics;2023-06-08

4. Molecular diagnostics and potential therapeutic options for mycobacterium tuberculosis: Where we stand;Medicine in Omics;2023-06

5. Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis;Frontiers in Pharmacology;2023-01-09